Problems of adherence to anticoagulant therapy in patients with ischemic stroke with the background of nonvalvular atrial fibrillation

фибрилляция предсердий, ишемический инсульт, факторы риска, шкала CHA₂DS₂VASc, антикоагулянтная терапия, atrial fibrillation, ischemic stroke, risk factors, CHA2DS2-VASc score, anticoagulant therapy

1. Kropacheva E.S. «Varfagen». 2014. In Russian. [Кропачева Е.С. «Варфаген». Selection of individual doses of warfarin: a summary of the findings of the Russian research. Подбор индивидуальной дозы варфарина: краткие выводы российского исследования. 2014].

2. Gilyarevsky S.R. The Ratio of the Pharmacological and Clinical Effects of Oral Anticoagulants as the Criterion of Choosing the Optimal Drug for Long-Term Prevention of Thromboembolic Complications. Kardiologiia = Cardiology. 2014; 12: 63-71. In Russian. [Гиляревский С.Р. Соотношение фармакологических и клинических эффектов перорального антикоагулянта как критерий выбора оптимального препарата для длительной профилактики тромбоэмболических осложнений. Кардиология. 2014; 12: 63-71].

3. Diagnostics and treatment of atrial fibrillation. Recommendations of RCS, RSSA, and ACVS. Ed. 2. 2012. In Russian. [Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ, выпуск 2, 2012 год].

4. Dispensary observation of patients with chronic non-infectious diseases and patients with a high risk of its development. Methodical recommendations. Eds. Boytcov S.A. and Chuchalin A.G. M.: 2014. p. 112. In Russian. [Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Под ред. С.А. Бойцова и А.Г. Чучалина. М.: 2014. c. 112].

5. Albers G.W., Sherman D.G., Gress D.R., Paulseth J.E., Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol. 1991;30(4): 511-518.

6. Chugh S.S, Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., Gillum R.F., Kim Y.H., McAnulty J.H. Jr., Zheng Z.J., Forouzanfar M.H., Naghavi M., Mensah G.A., Ezzati M., Murray C.J. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8): 837-847.

7. DeWilde S., Carey I.M., Emmas C., Richards N., Cook D.G. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92(8): 1064-1070.

8. Fang M.C., Stafford R.S., Ruskin J.N., Singer D.E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004; 164(1): 55-60.

9. Gladstone D.J., Bui E., Fang J., Laupacis A., Lindsay M.P., Tu J.V., Silver F.L., Kapral M.K. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009; 40(1): 235-240.

10. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12): 857-867.

11. Majeed A., Moser K., Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart. 2001; 86(3): 284-288.

12. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891.

13. Weitz J.I., Connolly S.J., Patel I., Salazar D., Rohatagi S., Mendell J., Kastrissios H., Jin J., Kunitada S. Randomised,parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104(3): 633-41.